ALT Altimmune, Inc. Insider Trading

Director John Gill bought 9,200 shares of ALT at $3.41, raising stake 73.6% to 21,700 shares amid cluster buying and -56.8% 52-week decline.

Director John Gill purchased 9,200 shares at $3.41 on 2026-04-06, increasing his holdings by 73.6% from 12,500 to 21,700 shares, while the stock trades at $3.33—down 56.8% from its 52-week high of $7.71. This buy occurs alongside a cluster of 2 other insider purchases within the past 14 days, suggesting coordinated board-level accumulation. However, Gill's prior buy at this ticker (2025-12-23) failed to anticipate a subsequent 90-day decline, and his broader cross-ticker track record shows a 0.00% win rate over 90-day windows despite one prior purchase. The company reported $-19.0M net income and $5.0K quarterly revenue, revealing an unprofitable profile even as full-year revenue grew 105.0%. The insider's significant stake increase during a depressed price environment and amid peer buying warrants tracking whether this reflects accumulation at suppressed valuations or alignment with other governance concerns.

CFO Weaver buys 10,000 ALT shares at $3.15; 30d down -25.0%, stock at 52w low range ($3.12 vs $7.71 high)

WEAVER GREGORY L, CFO of Altimmune, purchased 10,000 shares at $3.15 on 2026-04-01, increasing his holdings 35.6% from 28.1K to 38.1K shares. The transaction occurred amid significant stock weakness: the stock has declined -59.5% from its 52-week high of $7.71 to a current price of $3.12, with a particularly sharp -25.0% drop over the prior 30 days. The company's fundamentals present a mixed picture—revenue growth of 105.0% year-over-year is robust, but the company reported a net loss of $-19.0M on quarterly revenue of $5.0K, indicating an unprofitable operation with severe margin pressure. His prior buy at ALT on 2025-03-13 posted a 90-day return of +25.8%, and his cross-ticker track record shows a 100% 90-day win rate across 2 prior buys. However, the timing of this purchase—into a collapsing stock and an unprofitable business—warrants scrutiny of whether near-term fundamentals may remain challenged.

ALT CEO Jerome Benedict bought 15,000 shares at $3.14 on 2026-04-01; stock down -59.5% from 52-week high, company burning cash with -$19.0M net income.

Durso Jerome Benedict, the company's President and CEO, purchased 15,000 shares at $3.14, expanding his holdings by 46.2% to 47,500 shares. The purchase occurs while Altimmune trades at -59.5% from its 52-week high of $7.71, and the stock has declined -25.0% over the prior 30 days. The company's fundamentals remain challenged: Altimmune posted a -$19.0M net loss on $5.0K quarterly revenue and is unprofitable on a full-year basis, though annual revenue growth reached +105.0%. Against his own cross-ticker track record, this insider has achieved a 0.00% 90-day win rate across 2 prior open-market buys, with the most recent ALT purchase (2025-12-22) returning -19.0% at the 90-day mark. The pattern of repeated accumulation into a declining stock with negative earnings and minimal near-term revenue warrants monitoring of near-term execution and capital trajectory.

ALT CFO Gregory L Weaver buys 5,000 shares at $3.54 after 1-year 49.7% decline from $7.71 high

Gregory L Weaver, CFO of Altimmune, Inc., purchased 5,000 shares at $3.54 on 2026-03-06, increasing his holdings by 21.7% to 28,078 shares total. The buy occurs at a significant discount to the 52-week high of $7.71, with the stock currently -49.7% from that peak and -20.3% over the past 30 days. Weaver's prior buy at ALT on 2025-03-13 demonstrated positive 90-day performance (+25.8%), representing 1 of 1 well-timed buys in his open-market history at this ticker. However, context matters: the company reported revenue of $5,000.00 in its latest quarter against net losses of $-19,000,000.00 (full-year unprofitable), though annual revenue growth reached +105.0% year-over-year. The timing and magnitude of this accumulation merit scrutiny against the company's unprofitable state and recent price deterioration.

ALT CEO Jerome Benedict buys 20,000 shares at $3.54 (stock down 49.7% from 52-week high)

Jerome Benedict, President and CEO of Altimmune, purchased 20,000 shares at $3.54 on 2026-03-06, tripling his holdings from 12,500 to 32,500 shares. The purchase occurs at $3.54 while the stock trades 49.7% below its 52-week high of $7.71 and down 20.3% over the past 30 days. Altimmune remains unprofitable with a net loss of $-19,014,000.00 in its latest full fiscal year, though the company shows strong annual revenue growth of +105.0%. Benedict's prior open-market buy showed a +12.0% return within 30 days, though his track record lacks measurable positive outcomes at the 90-day mark. The timing and scale of this purchase merit monitoring given the company's unprofitability and recent significant stock decline.

Director Wayne Pisano bought 5.0K shares of ALT at $4.08 as part of cluster buy pattern; company down -47.9% from 52-week high amid -95.3% revenue collapse and $-19.0M net loss.

Wayne Pisano, a director, purchased 5,000 shares at $4.08 on 2026-01-08, increasing his holdings by 58.8% to 13,498 shares. This purchase is notable because two other insiders also bought within the past 14 days, establishing a cluster buy pattern at a time when the stock has declined -47.9% from its 52-week high of $7.71 and is trading 26.0% below its 30-day average. The timing warrants investor attention given the company's deteriorating fundamentals: annual revenue has collapsed -95.3% year-over-year to $5,000 in the latest quarter, and the company posted a $-19.0M net loss over its most recent full fiscal year. The convergence of multiple insider purchases during a sharp drawdown, combined with severe revenue contraction and continued losses, creates a pattern investors should monitor closely to understand management's conviction around turnaround prospects or asset stabilization.

Director Catherine A. Sohn bought 500 shares of Altimmune at $4.24; stock down 22% in 30 days, but director held winning prior trade.

Director Catherine A. Sohn purchased 500 shares at $4.24 on 2026-01-05, increasing her stake by 50.0% from 1,000 to 1,500 shares. The stock is currently trading at $4.09, down 22.0% over the past 30 days and 47.0% below its 52-week high of $7.71. Notably, Sohn's prior buy at this ticker (on 2025-03-17) generated a 90-day return of +19.6%, demonstrating successful timing on that occasion. The company faces material headwinds: revenue declined 95.3% year-over-year to $5.0K in the latest quarter, and the firm reported a net loss of $-19.0M over its most recent full fiscal year. A cluster of 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence at current valuations despite the deteriorated revenue environment.

Director Diane Jorkasky bought 527 ALT shares at $3.80; cluster pattern: 2 other insiders bought within 14 days

Diane Jorkasky, a director, purchased 527 shares of Altimmune at $3.80 on 2025-12-29, initiating a new position from zero prior holdings. This purchase is part of a cluster buy pattern, with 2 other insiders also acquiring shares within the past 14 days, suggesting coordinated or contemporaneous interest in the stock despite challenging fundamentals. The company reported revenue of $5,000.00 in its latest quarter and net income of $-19,014,000.00 over its most recent full fiscal year, with annual revenue declining 95.3% year-over-year, indicating severe operational distress. The stock is trading 54.0% below its 52-week high and has declined 30.0% over the past 30 days, providing context for insider purchases at a depressed price level relative to recent history.

Director John Gill purchases 12,500 shares of ALT at $4.10; stock down 51.5% from 52-week high, company burned $19.0M net in recent period with -95.3% annual revenue decline.

John Gill, a director at Altimmune, initiated a new position with a purchase of 12,500 shares at $4.10 on 2025-12-23, totaling $51,250.00. The purchase occurs in the context of significant headwinds: the stock has fallen 51.5% from its 52-week high of $8.25 and currently trades at $4.00, while fundamentals show the company recorded a net loss of $-19,014,000.00 in its most recent full fiscal year and revenue declined -95.3% year-over-year. This is a small absolute purchase relative to the company's $417,016,692.00 market capitalization, and the director had no prior shareholdings, so this represents entry rather than accumulation. The transaction alone does not provide sufficient signal strength given the shallow position size and the magnitude of underlying operational deterioration.

Director Durso buys 12,500 shares of ALT at $4.13; company burning cash with -$19.0M net income.

Director Jerome Benedict Durso acquired 12,500 shares at $4.13, entering the company with an initial stake during a period of financial distress. Altimmune's latest quarter showed revenue of $5,000.00 with net income of -$19.0M and annual revenue contraction of -95.3%, indicating a company in severe operational decline. The stock trades at -50.7% from its 52-week high of $8.40 and has declined 13.9% over the past 30 days, though it is up 9.2% over 90 days. This purchase by a newly-vested director merits attention to governance and capital allocation patterns at a pre-revenue or near-zero-revenue stage biotech company.